Kalydeco

Adult Dosing .

Dosage forms:  TAB: 150 mg

cystic fibrosis

[150 mg PO q12h]

Info: for patients with ivacaftor-responsive CFTR gene mutations; give with fat-containing food

renal dosing

[see below]

CrCl >31: no adjustment; CrCl <31: not defined, caution advised

HD/PD: not defined, caution advised

hepatic dosing

[adjust dose frequency]

Child-Pugh Class B: give usual dose q24h; Child-Pugh Class C: give usual dose q24h or less frequently

Peds Dosing .

Dosage forms:  TAB: 150 mg; GRANULE: 5.8 mg per packet, 13.4 mg per packet, 25 mg per packet, 50 mg per packet, 75 mg per packet

cystic fibrosis

[1-2 mo, >3 kg]

Dose: 5.8 mg PO q12h; Info: for patients with ivacaftor-responsive CFTR gene mutations; give with fat-containing food

[2-3 mo, >3 kg]

Dose: 13.4 mg PO q12h; Info: for patients with ivacaftor-responsive CFTR gene mutations; give with fat-containing food

[4-5 mo, >5 kg]

Dose: 25 mg PO q12h; Info: for patients with ivacaftor-responsive CFTR gene mutations; give with fat-containing food

[6 mo-5 yo, 5-6.9 kg]

Dose: 25 mg PO q12h; Info: for patients with ivacaftor-responsive CFTR gene mutations; give with fat-containing food

[6 mo-5 yo, 7-13.9 kg]

Dose: 50 mg PO q12h; Info: for patients with ivacaftor-responsive CFTR gene mutations; give with fat-containing food

[6 mo-5 yo, >14 kg]

Dose: 75 mg PO q12h; Info: for patients with ivacaftor-responsive CFTR gene mutations; give with fat-containing food

[6 yo and older]

Dose: 150 mg PO q12h; Info: for patients with ivacaftor-responsive CFTR gene mutations; give with fat-containing food

renal dosing

[see below]

CrCl >31: no adjustment; CrCl <31: not defined, caution advised

HD/PD: not defined, caution advised

hepatic dosing

[<6 mo]

hepatic impairment: avoid use

[6 mo and older]

Child-Pugh Class B: give usual dose q24h; Child-Pugh Class C: give usual dose q24h or less frequently